Every Spin-Off
Dermavon Holdings
AnnouncedHKSells prescription dermatology drugs, including ruxolitinib cream for vitiligo, and dermatology-grade skincare in mainland China.
CMS's skin-health business in mainland China (dermatology prescription drugs, including ruxolitinib cream, and dermatology-grade skincare), 90.8% owned by CMS.
- Status
- Announced
- Expected
- Timing not announced
- Parent
- China Medical System Holdings (867 HK)
- Spin-off ticker
- To be announced
- Listing
- Main Board of HKEX (by introduction)
- Market
- Hong Kong
- Sector
- Health care
Terms
Distribution in specie of CMS's entire 90.8% stake to shareholders pro rata and listing by introduction on the HKEX Main Board with no new shares offered; the 9.2% held by employee incentive platforms is excluded; ratio and record date not set; listing application filed 22 April 2025 and still described as proposed in the 2025 annual report (March 2026).
Key dates
- Spin-off announced, listing application filed
- Still proposed per 2025 annual report
- Record date and listing
Source documents
- Press releaseProposed spin-off and separate listing of Dermavon (04/22/25)
- PresentationNot yet published
- Prospectus / demerger documentNot yet public
- Sourcehkexnews.hk (CMS annual report 2025)
- Sourcekr-asia.com
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email